Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177

NCT05154890 is registered in ClinicalTrials.gov with Aeglea Biotherapeutics as lead sponsor.

NCT NCT05154890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05154890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177
Lead sponsor
Aeglea Biotherapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
May 13, 2021
Completion date
April 21, 2023
Enrollment
13 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

homocystinuria due to cystathionine beta-synthase deficiency